CARs to the rescue: rare aggressive lymphoma gets a power up.
作者信息
Kamdar Manali
机构信息
Division of Hematology and Bone Marrow Transplantation, University of Colorado, Aurora, CO.
出版信息
Blood Adv. 2024 Oct 22;8(20):5342-5343. doi: 10.1182/bloodadvances.2024014118.
Abstract
摘要
相似文献
1
CARs to the rescue: rare aggressive lymphoma gets a power up.嵌合抗原受体来救援：罕见侵袭性淋巴瘤获得助力。
Blood Adv. 2024 Oct 22;8(20):5342-5343. doi: 10.1182/bloodadvances.2024014118.
2
Current landscape for chimeric antigen receptor T cells in lymphomas.嵌合抗原受体 T 细胞在淋巴瘤中的现状。
Curr Opin Hematol. 2019 Nov;26(6):421-426. doi: 10.1097/MOH.0000000000000544.
3
Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.同种异体嵌合抗原受体疗法治疗淋巴瘤。
Curr Treat Options Oncol. 2022 Feb;23(2):171-187. doi: 10.1007/s11864-021-00920-6. Epub 2022 Feb 25.
4
FDA investigates risk of secondary lymphomas after CAR-T immunotherapy.美国食品药品监督管理局调查嵌合抗原受体T细胞免疫疗法后发生继发性淋巴瘤的风险。
Lancet Oncol. 2024 Jan;25(1):21. doi: 10.1016/S1470-2045(23)00631-9. Epub 2023 Dec 7.
5
CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond.急性淋巴细胞白血病中靶向CD19的嵌合抗原受体：现状与展望
Leuk Lymphoma. 2019 May;60(5):1346-1348. doi: 10.1080/10428194.2018.1533132. Epub 2019 Jan 16.
6
A review of chimeric antigen receptor T-cells in lymphoma.嵌合抗原受体 T 细胞在淋巴瘤中的研究进展。
Expert Rev Hematol. 2019 Jul;12(7):551-561. doi: 10.1080/17474086.2019.1629901. Epub 2019 Jun 19.
7
Cellular therapy in lymphoma.淋巴瘤的细胞治疗。
Hematol Oncol. 2024 Nov;42(6):e3200. doi: 10.1002/hon.3200. Epub 2023 Jun 29.
8
Perceived Cognitive Changes following Chimeric Antigen Receptor T Cell Therapy in Lymphoma: Perceptual Anticipation?嵌合抗原受体T细胞疗法治疗淋巴瘤后感知到的认知变化：感知预期？
Transplant Cell Ther. 2023 Jan;29(1):64. doi: 10.1016/j.jtct.2022.09.008. Epub 2022 Sep 21.
9
Response to: Perceived Cognitive Changes Following Chimeric Antigen Receptor T Cell Therapy in Lymphoma: Perceptual Anticipation?回应：嵌合抗原受体T细胞疗法治疗淋巴瘤后感知到的认知变化：感知预期？
Transplant Cell Ther. 2023 Jan;29(1):65. doi: 10.1016/j.jtct.2022.09.019. Epub 2022 Sep 27.
10
Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients.曙光初现：抗 PD-1 免疫疗法增强淋巴瘤患者嵌合抗原受体 T 细胞疗法。
BMC Cancer. 2023 Oct 23;23(1):1019. doi: 10.1186/s12885-023-11536-4.
本文引用的文献
1
CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma.CD19 靶向嵌合抗原受体 T 细胞治疗 T 细胞/组织细胞丰富型大 B 细胞淋巴瘤。
Blood Adv. 2024 Oct 22;8(20):5290-5296. doi: 10.1182/bloodadvances.2024013863.
2
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.Tisagenlecleucel 治疗复发或难治性侵袭性 B 细胞淋巴瘤患者的长期临床结局（JULIET）：一项多中心、开放标签、单臂、2 期研究。
Lancet Oncol. 2021 Oct;22(10):1403-1415. doi: 10.1016/S1470-2045(21)00375-2. Epub 2021 Sep 10.
3
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.T细胞/组织细胞丰富的大B细胞淋巴瘤对CD19导向的嵌合抗原受体T细胞疗法的原发性耐药
Blood. 2021 Jun 17;137(24):3454-3459. doi: 10.1182/blood.2020009148.
4
Immune escape mechanisms for TCRLBCL.TCRLBCL 的免疫逃逸机制。
Blood. 2021 Mar 11;137(10):1274-1276. doi: 10.1182/blood.2020008766.
5
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.西达基奥仑赛治疗复发或难治性大 B 细胞淋巴瘤患者的疗效和安全性（TRANSCEND NHL 001）：一项多中心无缝设计研究。
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
6
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
Zotero 插件